ACAD
41.38
+1.52
+3.81%
AEMD
6.6
+0.05
+0.76%
APRI
1.71
+0.04
+2.40%
ARNA
4.42
+0.12
+2.79%
ATEC
1.381
+0.001
+0.1014%
CNAT
5.1
-0.01
-0.20%
CRXM
0.388
+0.011
+2.890%
CYTX
0.561
+0.001
+0.2143%
DXCM
79.918
+0.818
+1.0345%
GNMK
9.22
+0.12
+1.32%
HALO
22.03
+0.79
+3.72%
ILMN
218.09
+4.11
+1.92%
INNV
0.117
0.00
0.00%
INO
8.1
+0.11
+1.38%
ISCO
0.041
0.00
0.00%
ISIS
56.05
0.00
0.00%
LGND
100.2
+3.4
+3.51%
LPTN
0.261
+0.001
+0.3849%
MBVX
2.34
+0.01
+0.43%
MEIP
1.69
-0.01
-0.59%
MNOV
4.02
+0.05
+1.26%
MRTX
31.36
+0.5
+1.62%
MSTX
0.465
-0.005
-1.0430%
NBIX
45.81
0.00
0.00%
NUVA
47.81
+0.21
+0.44%
ONCS
6.49
+0.07
+1.0935%
ONVO
3.794
+0.144
+3.945%
OREX
4.75
+0.21
+4.63%
OTIC
21.27
+0.17
+0.81%
QDEL
23.08
+0.23
+1.01%
RCPT
176
0.00
0.00%
RGLS
10.44
+0.33
+3.26%
RMD
56.15
+0.71
+1.28%
SCIE
0.018
-0.001
-4.3716%
SPHS
0.83
+0.02
+2.47%
SRNE
17.04
+0.47
+2.84%
TROV
9.63
+0.4
+4.33%
VICL
0.71
+0.01
+1.43%
ZGNX
1.64
+0.02
+1.23%
ACAD
41.38
+1.52
+3.81%
AEMD
6.6
+0.05
+0.76%
APRI
1.71
+0.04
+2.40%
ARNA
4.42
+0.12
+2.79%
ATEC
1.381
+0.001
+0.1014%
CNAT
5.1
-0.01
-0.20%
CRXM
0.388
+0.011
+2.890%
CYTX
0.561
+0.001
+0.2143%
DXCM
79.918
+0.818
+1.0345%
GNMK
9.22
+0.12
+1.32%
HALO
22.03
+0.79
+3.72%
ILMN
218.09
+4.11
+1.92%
INNV
0.117
0.00
0.00%
INO
8.1
+0.11
+1.38%
ISCO
0.041
0.00
0.00%
ISIS
56.05
0.00
0.00%
LGND
100.2
+3.4
+3.51%
LPTN
0.261
+0.001
+0.3849%
MBVX
2.34
+0.01
+0.43%
MEIP
1.69
-0.01
-0.59%
MNOV
4.02
+0.05
+1.26%
MRTX
31.36
+0.5
+1.62%
MSTX
0.465
-0.005
-1.0430%
NBIX
45.81
0.00
0.00%
NUVA
47.81
+0.21
+0.44%
ONCS
6.49
+0.07
+1.0935%
ONVO
3.794
+0.144
+3.945%
OREX
4.75
+0.21
+4.63%
OTIC
21.27
+0.17
+0.81%
QDEL
23.08
+0.23
+1.01%
RCPT
176
0.00
0.00%
RGLS
10.44
+0.33
+3.26%
RMD
56.15
+0.71
+1.28%
SCIE
0.018
-0.001
-4.3716%
SPHS
0.83
+0.02
+2.47%
SRNE
17.04
+0.47
+2.84%
TROV
9.63
+0.4
+4.33%
VICL
0.71
+0.01
+1.43%
ZGNX
1.64
+0.02
+1.23%
Home » John Finn Biography

John Finn Biography

Dr. Finn holds a B.S. in chemistry from Villanova University and a Ph.D. in organic chemistry from the University of Illinois. He spent the first ten years of his industrial career as doing optimization chemistry for American Cyanamid. In 1995, He moved to Synaptic Pharmaceutical as an associate director of medicinal chemistry at Synaptic Pharmaceutical focusing on drugs targeting novel GPCR targets. From 1998 to 2004, Dr. Finn held various leadership positions at Cubist Pharmaceuticals and Elitra Pharmaceuticals, two biotech companies focusing on novel antibacterial agents. Dr. Finn has served as the chief scientific officer of Trius since February 2007 and is a co-founder of our company. From July 2004 to February 2007, he served as the president.